Misleading and confusing fees imposed by drug plan middlemen distort prescription drug prices for everyone. These clawbacks, or "DIR fees", also threaten independent community pharmacies.
However, new bipartisan legislation has been introduced in both the United States Senate and House of Representatives to address "DIR fees." S. 3308/H.R. 5951, the Improving Transparency and Accuracy in Medicare Part D Spending Act, would prohibit retroactive "DIR fees" on pharmacies in Medicare Part D. Medicare officials can also enact guidance to require transparency into these fees.
For more information:
What You Can Do